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Background: Stereotactic body radiation therapy (SBRT) is an emerging treatment option for liver tumors. This
study evaluated outcomes after SBRT to identify prognostic variables and to develop a novel scoring system
predictive of survival.
Methods: The medical records of 52 patients with a total of 85 liver lesions treated with SBRT from 2003 to 2010
were retrospectively reviewed. Twenty-four patients had 1 lesion; 27 had 2 or more. Thirteen lesions were primary
tumors; 72 were metastases. Fiducials were placed in all patients prior to SBRT. The median prescribed dose was
30 Gy (range, 16 – 50 Gy) in a median of 3 fractions (range, 1–5).
Results: With median follow-up of 11.3 months, median overall survival (OS) was 12.5 months, and 1 year OS was
50.8%. In 42 patients with radiographic follow up, 1 year local control was 74.8%. On univariate analysis, number of
lesions (p = 0.0243) and active extralesional disease (p < 0.0001) were predictive of OS; Karnofsky Performance Status
(KPS) approached statistical significance (p = 0.0606). A scoring system for predicting survival was developed by
allocating 1 point for each of the three following factors: active extralesional disease, 2 or more lesions, and
KPS≤ 80%. Score was associated with OS (p < 0.0001). For scores of 0, 1, 2 and 3, median survival intervals were 34,
12.5, 7.6, and 2.8 months, respectively.
Conclusions: SBRT offers a safe and feasible treatment option for liver tumors. A prognostic scoring system based
on the number of liver lesions, activity of extralesional disease, and KPS predicts survival following SBRT and can be
used as a guide for prospective validation and ultimately for treatment decision-making.
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The liver is a common site for metastatic disease from mul-
tiple primary tumors, including colorectal, breast, and lung
cancer. Historically, limited metastatic disease was managed
with surgical resection, with 5-year survival up to 67% [1,2].
However, surgery is an option only for patients with limited
disease and adequate performance status, which may be as
few as 10-20% of patients with hepatic metastases [1,3-5].
Primary liver tumors are managed similarly, with resection
providing the only potentially curative option. However,
patients with metastatic, primary, or recurrent liver tumors* Correspondence: Marie-Adele.S.Kress@gunet.georgetown.edu
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reproduction in any medium, provided the ornot amenable to resection are candidates for local treat-
ments including radiofrequency ablation (RFA), trans-
arterial chemo-embolization (TACE), or stereotactic body
radiation therapy (SBRT), which are increasingly used with
the goal of achieving local control.
Modern, conventional radiation therapy (RT) has
improved upon historical approaches by improving con-
formality and minimizing dose to normal liver [6]. How-
ever, due to respiratory motion and set-up uncertainty,
even these modern techniques are limited in terms of
their potential for dose-escalation and effective tumor
control. SBRT has been employed for the treatment of
inoperable, limited tumors in the lungs, brain, and other
sites of oligometastatic or limited primary disease [7-10].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics
Characteristic n
Total patients (n) 52
Total lesions 85
Sex (n) (per patient)
M 29
F 23
Age (y) (per patient)
Median 56
Range 37-91
Number of liver lesions (per patient)
One 24
Two 9
Three or more 18
Karnofsky Performance Status (KPS)
Median 90
Range 50-100
Status of systemic disease
Active 24
Inactive 28
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of limited liver metastases [11-14].
Despite growing evidence supporting SBRT as safe and
effective for local control of liver lesions, little is known
regarding optimal patient selection for this treatment
modality. In other sites of metastatic disease, algorithms
or scoring systems have been developed to identify can-
didates for radiation therapy and to establish patients’
prognoses, such as the Recursive Partitioning Analysis
or Diagnosis-Specific Graded Prognostic Assessment
classes used in the treatment of patients with brain me-
tastases [15,16].
In this study, we aimed to review clinical outcomes of
patients treated with SBRT for liver lesions and to de-
velop a novel scoring system to predict overall survival
(OS) and to guide treatment decision-making.
Methods
Patient selection
This retrospective review was approved by the Institu-
tional Review Board (IRB) of Georgetown University.
Eight-five lesions in 52 consecutive patients treated
with SBRT for liver metastases between November,
2004 and June, 2009 were identified from treatment
records at Georgetown University Hospital’s Depart-
ment of Radiation Oncology. No patients were consid-
ered candidates for surgical resection. Lesions were
considered for treatment in any location within the
liver, including right, left, and caudate lobes, as well as
proximal to the porta hepatis. All histologies were
included, including metastatic and primary liver
tumors. Patients were included irrespective of prior
treatment. Patients generally were excluded for inad-
equate hepatic function. Patients were generally seen
in regular follow-up for clinical and radiologic assess-
ments at the discretion of the treating radiation and
medical oncologists every 3 to 6 months. Initial radiologic
follow-up included contrast-enhanced CT scan, MRI, and/
or PET/CT scan and was typically 2–4 months after com-
pletion of CyberKnife SBRT.
SBRT planning and treatment
SBRT planning and treatment techniques have been
detailed previously [17]. Three to five gold fiducials
were placed in or near liver tumors under CT guidance
(Best Medical, Springfield, VA). A treatment planning
CT scan with slice thickness of 1 – 3 mm was obtained at
least 5 days after fiducial placement. Patients were simu-
lated in the supine position. Gross tumor volume (GTV)
was delineated on the CT scan. Typically, margins of at
least 3–5 mm were added to the GTV to form the clinical
target volume (CTV) [18]. No additional margin was added
to form the planning target volume (PTV). Adjacent critical
structures were delineated.All treatments were performed using the CyberKnife
system and were planned using Multiplan treatment
planning software. Radiation plans and prescriptions
were developed using inverse-planning. Treatments
were delivered using 6MV photons and were prescribed
to an isodose line that provided adequate PTV coverage
(> 95%). Synchrony Respiratory Tracking System was
used to continuously track fiducial position and adjust
for respiratory motion. Patients were treated to a me-
dian dose of 30 Gy (range: 16 – 50 Gy), in a median of
3 fractions (range: 1–5). A biologic equivalent dose
(BED) was calculated for each fractionation scheme by
the formula: BED10 = (Prescription dose) * (1+ (Dose
per fraction / α/β)); where α/β is assumed to be 10.
Data analysis
Treatment response was evaluated by serial CT, PET,
and/or MRI scans. Estimates of initial treatment re-
sponse were determined using the Response Evaluation
Criteria in Solid Tumors (RECIST) [19]. Local control
was defined as no evidence of tumor growth of the trea-
ted lesion. Actuarial survival and local control rates were
evaluated by the Kaplan-Meier method. Univariate ana-
lysis (UVA) was performed with the logrank test; multi-
variate analysis (MVA) was performed using Cox
proportional-hazards regression. Based on the UVA ana-
lysis a prognostic scoring system for survival was devised
whereby the presence of the following increased the
score by one point each: presence of active systemic
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were evaluated according to the Common Terminology
Criteria for Adverse Events (CTCAE), Version 4.0 [20].
Toxicities occurring less than or equal to 3 months fol-
lowing SBRT were considered acute, while toxicities oc-
curring after 3 months were considered late.Results
Patient and lesion characteristics
Patient characteristics are noted in Table 1. The median
age at treatment was 56. Eighty-nine percent of lesions
had not been treated in the past. The median Karnofsky
Performance Status (KPS) at the time of treatment was 90
(range, 50–90). Thirty-six patients had good KPS (90-
100%), while 14 patients had KPS of 80 or less, with only 2
patients demonstrating poor KPS (50-60%). Twenty-four
patients only had one liver lesion at the time of SBRT, while
9 had two lesions, and 18 had three or more. Twenty-fourTable 2 Lesion characteristics
Characteristic n

















Squamous cell carcinoma of the head and neck 4
Malignant meningioma 2
Adenocarcinoma of unknown primary 2
Transitional cell 2





Uterine 1patients (46%) had active systemic, extrahepatic disease at
the time of SBRT, while the remainder did not.
Lesion characteristics are noted in Table 2, and dosimet-
ric parameters are presented in Table 3. Most lesions were
treated using a fractionated approach, with a median of 3
fractions (range, 1–5). The BED10 varied widely, with a me-
dian effective dose of 60 Gy (range, 28 – 113 Gy), which is
equivalent to a median dose of 50 Gy (range, 23 – 94 Gy)
using standard (2 Gy) fractionation. Lesion size also varied
greatly, with a median treatment volume of 32 cm3.
Clinical outcomes
With a median follow-up of 11.3 months (range, 1–
67 months), the median actuarial overall survival was
12.5 months, with a one-year actuarial survival of 50.8%
(Figure 1). Twelve patients with a total of 14 lesions had
no radiographic follow-up. Among those with post-
treatment imaging, local control was excellent, with me-
dian time to failure of 35.5 months and actuarial 1-year
local control of 74.8% (Figure 2).
BED10 > 75 Gy, primary versus metastatic lesion, target
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Figure 1 Overall survival by patient.
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relation with local control. Of these variables, only small
volume was associated with improved local control on
univariate (p = 0.0449) and multivariate (p = 0.0295)
analyses.
On (UVA), reported in Table 4, the number of lesions
(1 vs. 2 or more) (p= 0.0243) and active systemic dis-
ease (p < 0.0001) were predictive of survival. Status of
tumor as primary vs. metastasis was also evaluated, but
was not found to be associated with survival (Table 4).Loc
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Figure 2 Local control by lesion.KPS (80 or less vs. 90–100) approached statistical sig-
nificance (p= 0.0606). A scoring system was developed,
whereby each of the following factors increased the
patient’s score by one point: 2 or more lesions, active
systemic disease, and KPS of 80 or less. As shown in
Figure 3, this scoring system was predictive of OS.
Median survival by score was 34.4 months, 12.5 months,
7.6 months, and 2.8 months for scores of 0, 1, 2, and
3, respectively. On MVA, patient score was the only
factor predictive of survival (p < 0.0001).al Control
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1 vs. 2 or more 0.0243
Active Systemic Disease <0.0001
Karnofsky Performance Status (KPS)
80 or less vs. 90-100 0.0606




Primary vs. metastasis 0.6423
Histology 0.5644
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Overall, 11.5% of patients experienced grades 3/4 acute
toxicities. Grade 4 elevation in bilirubin was experienced
by one patient, followed by early death due to tumor
progression. This patient also had grades 1, 2, and 3 ele-
vations in alanine aminotransferase (ALT), alkaline
phosphatase, and aspartate aminiotransferase (AST),
respsectively. There was one grade 3 toxicity due to acal-
culous cholecystitis that required percutaneous drainage
and treatment with antibiotics. There were 4 additional
grade 3 elevations of bilirubin, and one of those patientsS
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Figure 3 Survival by prognostic score.also had a grade 3 elevation of alkaline phosphatase.
Grade 1–2 toxicities were common and included right
upper quadrant abdominal pain, anorexia, weight loss,
liver enzyme elevations, fatigue, nausea, vomiting, and
gastritis. No patients required treatment interruptions
due to toxicity.Discussion
Stereotactic body radiation therapy (SBRT) has been
demonstrated to be feasible and safe for treatment of
liver tumors in multiple retrospective and a few pro-
spective series [11-14,21,22]. A single-institution Phase I
study established the safety of single fraction SBRT with
no grade 3 or higher toxicities, 1-year local control of
77%, and median overall survival of 28.6 months [23]. A
multi-institutional Phase I/II study demonstrated limited
toxicity (2% grade 3 or higher) and excellent in-field
local control at two years (92%), which improved with
small lesion size (100% at two years), with a median sur-
vival of 20.5 years [24]. A larger Phase I-II study did not
reach dose-limiting toxicity, with a total of 13% of
patients with grades 3–4 toxicity, and no grade 5 tox-
icity; 1-year local control was 71%, with 17.6 months
median overall survival [25].
Our study compares favorably with these prospective
and retrospective studies. Although the lower median sur-
vival may relate to the significant number of patients with
compromised performance status and active extrahepaticurvival
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of 74.8% is comparable with published series. Retrospective
reports have demonstrated 1 to 2-year local control ran-
ging from 57-92%, with median survival ranging from
14.5-34 months [21,22,26-28]. However, this heteroge-
neous group of patients may be expected to have widely
variable clinical outcomes.
Despite the growing interest in using SBRT to treat
hepatic metastases, little is known about optimal patient
selection or prognosis. In the setting of high long-term
local control rates, it becomes of paramount importance
to select patients who may optimally benefit from local
control and omit those who would be unlikely to clinic-
ally benefit from treatment.
Clinical scoring systems have been used to prognosti-
cate outcomes for patients with metastatic disease in
other sites. One prominent example is the use of Recur-
sive Partitioning Analysis (RPA) or Diagnosis-Specific
Graded Prognostic Assessment (DS-GPA) for patients
with brain metastases [15,16]. RPA classes were deter-
mined by Karnofsky Performance Status (KPS), age, and
status of primary and extracranial metastases [15].
DS-GPA factors vary by primary diagnosis, but all scores
incorporate KPS, while scores for non-small cell lung cancer
(NSCLC), small cell lung cancer (SCLC), melanoma,
and renal cell cancer incorporate the number of brain
lesions, while NSCLC and SCLC also incorporate the
status of extracranial metastases [16].
Surgical series have examined pre- and peri-operative
prognostic factors in the setting of hepatic metaste-
ctomy. One study demonstrated that predictors of long-
term outcome included extrahepatic disease status,
number and size of hepatic tumors [29]. The authors of
this study demonstrated that a preoperative scoring sys-
tem combining carcinoembryonic antigen level, number
and size of tumors, disease-free interval from primary to
metastases and lymph node status of primary was pre-
dictive of survival [29]. A similar published study
observed that 10 separate factors were associated with
surgical outcome from hepatectomy. These factors
included patient age, tumor histology, length of disease-
free interval between treatment of primary tumor and
metastases, presence of extrahepatic disease, response to
pre-operative chemotherapy, time period of treatment,
and surgical factors [30]. The authors also developed a
risk model, based on these 10 characteristics, that was
correlated with estimated 5-year survival [30]. Our study
utilizes some of the same factors used in these scoring
systems, such as performance status and extralesional
disease status, but combines them in a simple, clinically
accessible model. However, one limitation of our scoring
system is that it has been developed using only a retro-
spective data set. As a result, this system’s utility in
evaluating candidates for hepatic SBRT warrantsvalidation with a prospective cohort and for individual
disease subtypes.
Other local therapy options have been evaluated for use
in the setting of limited hepatic metastases, one of the
most common of which is radiofrequency ablation (RFA).
As with SBRT, outcomes following RFA have been shown
to be related to the number and size of hepatic tumors
[31]. Previous studies have demonstrated that the extrahe-
patic disease status and primary tumor site correlated with
survival following liver SBRT [24,32].
From these historical scoring systems and review of
outcomes following local therapies, including SBRT, it is
evident that there may be many significant factors that
relate to survival in the setting of treating patients with
limited metastatic disease. Performance status, status of
extralesional disease, and number of lesions, the three
factors utilized in our novel scoring system, are com-
monly used in the systems discussed above. The novel
scoring system presented in this paper represents a po-
tential paradigm-shift in patient selection for SBRT.
However, this system is hypothesis-generating since it is
based on retrospective data. This system needs to be
validated with a prospective patient cohort and matched
with information regarding patient-reported quality of
life outcomes and step-wise approaches to additional
local, regional, and systemic therapy.
Conclusions
SBRT is a safe and feasible treatment option for liver
tumors. A prognostic scoring system that includes the
number of liver lesions, activity of extralesional disease,
and KPS predicts overall survival following liver SBRT.
This system will benefit from further refinement with a
prospective cohort to add specificity regarding progno-
ses for individual pathologic subtypes and in the pres-
ence of combination therapy.
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